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ABsTrACT
Objectives Controlled immune responses rely 
on integrated crosstalk between cells and their 
microenvironment. We investigated whether targeting 
proinflammatory signals from the extracellular matrix 
that persist during pathological inflammation provides a 
viable strategy to treat rheumatoid arthritis (rA).
Methods Monoclonal antibodies recognising the 
fibrinogen-like globe (FBG) of tenascin-C were generated 
by phage display. Clones that neutralised FBG activation of 
toll-like receptor 4 (tLr4), without impacting pathogenic 
tLr4 activation, were epitope mapped by crystallography. 
Antibodies stained synovial biopsies of patients at different 
stages of rA development. Antibody efficacy in preventing 
rA synovial cell cytokine release, and in modulating 
collagen-induced arthritis in rats, was assessed.
results tenascin-C is expressed early in the 
development of rA, even before disease diagnosis, with 
higher levels in the joints of people with synovitis who 
eventually developed rA than in people whose synovitis 
spontaneously resolved. Anti-FBG antibodies inhibited 
cytokine release by rA synovial cells and prevented 
disease progression and tissue destruction during 
collagen-induced arthritis.
Conclusions early changes in the synovial 
microenvironment contribute to rA progression; blocking 
proinflammatory signals from the matrix can ameliorate 
experimental arthritis. these data highlight a new drug 
class that could offer early, disease-specific immune 
modulation in rA, without engendering global immune 
suppression.
InTrOduCTIOn
Environmental signals play a key role in shaping 
cell identity, imprinting tissue-specific gene expres-
sion programmes to enable geographically adapted 
cell behaviour. This includes, for example, speciali-
sation of gut and brain macrophages, or of synovial 
and dermal fibroblasts, to fulfil distinct site-specific 
roles.1 2 Dynamic tissue remodelling during inflam-
mation creates new microenvironmental niches 
designed to drive immune responses that restore 
homeostasis. These temporary structures comprise 
specialised extracellular matrix molecules that 
support infiltrating immune cells and proliferating 
tissue resident cells, pattern soluble effector mole-
cules and signal to cells to orchestrate controlled 
inflammation.3 4 Immunomodulatory matrix mole-
cules exhibit restricted expression in healthy tissue, 
but are persistently expressed at sites of patholog-
ical inflammation, leading to their exploitation in 
the clinic as disease-specific postcodes with which 
to deliver antibody-linked packages of cytotoxic 
and anti-inflammatory drugs.5 Here, we determined 
whether directly targeting the activity of these matrix 
molecules could combat pathological inflammation.
Tenascin-C is a large, multimodular extracellular 
matrix molecule that exhibits limited expression 
in healthy tissues but is transiently upregulated 
on cellular stress and tissue injury, where it trig-
gers inflammation by activating toll-like receptor 
4 (TLR4). Persistent expression of tenascin-C has 
been implicated as a driver of chronic inflamma-
tion in autoimmune, neurological, metabolic and 
Key messages
What is already known about this subject?
 ► Immunomodulatory signals from the 
extracellular matrix help to shape immune 
responses. Activation of toll-like receptor 
4 (TLR4) by tenascin-C, a matrix molecule 
persistently expressed at high levels in people 
with RA, drives chronic inflammation in models 
of rheumatoid arthritis (RA).
What does this study add?
 ► We developed monoclonal antibodies that 
block the TLR4 binding epitope within the 
fibrinogen-like globe domain of tenascin-C; 
these antibodies inhibit cytokine release by RA 
synovial cells and prevent disease progression 
and tissue destruction during collagen-induced 
arthritis.
How might this impact clinical practice?
 ► This study indicates that antibodies targeting 
proinflammatory signals from the extracellular 
matrix should be further explored for use in 
clinical practice for treating RA.
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Figure 1 Generation and affinity maturation of anti-tenascin-C antibodies. (A) Fab clones were screened for their ability to inhibit FBG-mediated 
upregulation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) in THP1-blue cells. (B) The potency of top hits (clones 15, 17 
and 20) was further assessed compared with control Fab D1.3 recognising hen egg lysozyme. (A and B) Data are shown as the mean±SD from three 
experiments. (C) The binding affinity of NSC20 to human FBG was analysed by surface plasmon resonance (SPR) spectroscopy at 25°C. (D) Following 
affinity maturation, NSC20 variants were screened for improved binding to human and mouse FBG. HTRF measured the ability of affinity matured 
scFv clones to compete with labelled NCS20 IgG for antigen binding. Data are presented as percentage inhibition of the FRET signal (x-axis). The ENC 
assay used limiting amounts of immobilised anti-FLAG antibody to capture FLAG-tagged scFv from culture supernatants and thereby normalise the 
amount of immobilised scFv. After washing to remove excess (unbound) scFv, the ability of immobilised antibody clones to bind biotinylated CD4-his-
mTNC-FBG was detected by DELFIA, allowing ranking of clones based on affinity. Parental NSC20 was used as a benchmark, and data are presented 
as fold-increase in fluorescence signal (y-axis). Open circles represent NSC20 variants, solid green circle indicates lead variant, C3. (E) The heavy 
chain CDR3 (HCDR3) sequence and binding properties, determined by SPR at 37°C, of C3 are shown compared with the parental antibody NSC20. 
In contrast to NSC20, no measurable dissociation of the antibody–antigen complex was detectable over a 10 min period at 25°C for C3 (data not 
shown). Hence, affinity values for C3 were determined at 37°C. ENC, expression-normalised capture; FBG, fibrinogen-like globe; HTRF, homogeneous 
time resolved fluorescence.
fibrotic diseases, in which expression levels can predict prog-
nosis and reflect treatment outcome.6 In patients with rheu-
matoid arthritis (RA), high tenascin-C is associated with more 
erosive joint disease and predicts poor response to biological 
treatment.7 During experimental joint disease, mice lacking 
tenascin-C are protected from prolonged synovial inflammation 
and tissue destruction; while inflammation is induced in these 
animals, it is also swiftly resolved, concomitant with downreg-
ulation of key inflammatory cytokines and pathogenic T cell 
subsets.8 9
Mapping the active domain within tenascin-C revealed a 
unique structural epitope in the fibrinogen-like globe (FBG) 
that is essential for binding to and activating TLR4.8 10 Distinct 
modes of receptor activation and diverse downstream signalling 
induced by FBG compared with pathogenic TLR4 agonists,11 
revealed an opportunity to ablate pathological ‘sterile’ inflamma-
tion, leaving intact host defence against infection. We reasoned 
that this makes tenascin-C an attractive candidate for safely 
modulating inflammatory signals from the microenvironment. 
However, lack of specific, effective antagonists that block FBG 
activation of TLR4 have precluded assessment of tenascin-C as a 
viable therapeutic target.
MeTHOds
All methods are provided in the online supplementary mate-
rials section.
resulTs
Generating neutralising anti-tenascin-C antibodies
We generated monoclonal antibodies against the FBG domain 
of human tenascin-C using phage display. A panel of 20 
sequence unique antibodies that bound to the FBG domain of 
tenascin-C, but not tenascin-R, the family member possessing 
the most closely related FBG domain, were selected for conver-
sion into Fab format. Fabs were tested for blockade of nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-κB) 
activity induced in human monocytic THP1 reporter cells by 
stimulation with the FBG domain of tenascin-C (figure 1A). 
Titration of selected antibodies revealed a half maximal 
inhibitory concentration (IC50) of 1.7 nM for clone NSC20 
(figure 1B). NSC20 bound to the FBG domain of human tena-
scin-C with high affinity (KD 110 pM at 25°C) (figure 1C) and 
bound comparably well to canine FBG; however, binding to 
rodent FBG domains was 117-fold less (data not shown). To 
generate antibodies whose efficacy could be assessed in human 
and rodent models of disease, NSC20 was affinity matured. 
Among 138 individual NSC20 variants whose binding was 
analysed using homogeneous time resolved fluorescence 
competition and expression-normalised capture (ENC) assays 
(figure 1D), clone C3 exhibited a KD for the FBG domain of 
human tenascin-C of 70 pM and recognised rat antigen with a 
KD of 1.2 nM (figure 1E).
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Figure 2 Defining the mode of action of neutralising anti-tenascin-C antibodies. (A and B) The crystal structure of C3 bound to the FBG domain of 
human tenascin-C. Six FBG residues bind to Fab chain B (heavy chain) (A2115, Y2116, R2147, R2151, N2118 and H2171) and 13 FBG residues with 
Fab chain C (light chain) (Y2116, S2131, I2133, Y2140, R2147, N2148, C2149, H2150, R2151, H2163, S2164, F2170 and H2175), three of which are 
shared (Y2116, R2147 and R2151). Light green: FBG residues in contact with Fab chain B; dark green: FBG residues in contact with Fab chain C; blue: 
FBG residues in contact with Fab chains B and C. This interaction interface is not conserved in the FBG domains of tenascin-R and tenascin–W. Only 
9 of these 16 residues are present in FBG-R, and only seven in FBG-W. Of the three residues in FBG-C that interact with both heavy and light chain 
of the antibody, one residue is substituted in FBG-R, and all three are substituted in FBG-W. These data support experimental evidence that FBG-R 
does not bind to C3, and the higher sequence divergence of the FBG domain of tenascin-W with that of tenascin-C (54.1%) compared with tenascin-R 
(61.6%), and the fact that this divergence includes key positions in the C3 binding epitope, predicts that FBG-W will also be unable to bind to C3. (C) 
Recombinant human TLR4 was coated onto a 96-well plate, and recombinant human tenascin-C FBG, which had been preincubated with C3 or isotype 
control antibody, was added. Bound FBG was detected, and the percentage inhibition in the C3 preincubated samples was calculated compared 
with the isotype control samples (IC50=45.5 nM). Data are shown as the mean±SEM from eight experiments. (D) Recombinant human tenascin-C 
FBG (FBG) (1 µM) or lipopolysaccharide (LPS) (1 ng/mL) were preincubated with the indicated doses of C3 or isotype control antibody (Ig) before 
being added to primary human macrophages. After 24 hours, supernatants were taken, and cytokine ELISAs were performed. Data are shown as the 
mean±SEM from four independent donors. One-way analysis of variance was performed to determine significance of C3 inhibition compared with 
isotype control. *p<0.05, **p<0.01, ****p<0.0001. FBG, fibrinogen-like globe; IL, interleukin; TLR4, toll-like receptor 4; TNF, tumour necrosis factor.
defining antibody mode of action
Crystallisation of the FBG domain of human tenascin-C in 
complex with Fab fragments of C3 revealed interactions 
in the X-ray structure are mediated by hydrogen bonds and 
three layer pi:pi stacking, predominantly between one of 
the two Fab chains (figure 2A,B). Comparison of the TLR4 
binding epitope10 with the Fab epitope in FBG predict that 
antibody binding will abrogate tenascin-C’s ability to activate 
TLR4 by preventing access of the receptor to residues (S2131 
and I2133) in FBG that are required for optimal binding to 
TLR4. This was validated experimentally by demonstration 
that preincubation of FBG with C3 inhibits binding of FBG 
to purified recombinant TLR4 in a solid phase binding assay 
(IC50 45.56 nM)(figure 2C) and that preincubation of FBG 
with C3 blocks the ability of FBG to induce cytokine synthesis 
in primary human macrophages, while C3 had no effect on 
LPS-induced cytokine release (figure 2D).
Assessing antibody efficacy in synovial cells from patients 
with rA and in experimental arthritis
Staining with anti-FBG antibodies was observed in synovial 
biopsies from people with joint inflammation; tenascin-C levels 
were higher in people with early RA, compared with people 
who had joint inflammation that spontaneously resolved and 
who did not develop RA, or patients with established RA 
(figure 3A). FBG staining was predominantly observed in the 
sublining synovial layer of inflamed tissue where it created 
a dense matrix surrounding both podoplanin-positive and 
CD90-positive fibroblasts. FBG staining was also associated 
with blood vessels, lying underneath and around the CD31+ 
endothelial cell layer (figure 3B). Costaining of the C-terminal 
FBG domain with antibodies that recognise the N-terminal 
epidermal growth factor-like (EGF-L) repeats of tenascin-C 
revealed largely overlapping localisation and also highlighted 
areas where anti-FBG staining predominated (online supple-
mentary figure 1). In mixed cell populations isolated from the 
synovium of patients with RA undergoing joint replacement, 
monoclonal antibody C3 blocked cytokine release induced by 
stimulation with FBG, but not LPS (figure 3C). Rats in which 
joint inflammation was induced by intradermal administration 
of type II collagen (day 0 and day 7) were treated twice weekly 
with vehicle (PBS), isotype control (10 mg/kg) or C3 (1, 3 
or 10 mg/kg) from day 0 until the end of the experiment at 
day 28. No significant differences between vehicle and isotype 
control groups were observed for any parameter measured. 
However, increasing doses of C3 significantly reduced clinical 
score (figure 3D) and paw swelling (figure 3E). In addition, C3 
treatment reduced the number of affected paws per animal; 
rats with only one affected paw were restricted to the 3 mg/
kg and the 10 mg/kg C3 groups, and rats treated with 10 mg/
kg C3 gained significantly more weight throughout the experi-
ment (not shown). Finally, C3 treatment reduced the incidence 
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Figure 3 Antibody treatment ameliorates inflammation in experimental arthritis. (A and B) Synovial biopsies from the Birmingham early arthritis 
cohort were stained with anti-FBG antibodies. Quantification of the number of positive pixels per microgram biopsy was performed in tissue from 
people with early RA (undiagnosed synovitis of less than 3 months, patients who go on to be diagnosed with RA), people with synovial inflammation 
that spontaneously resolved (undiagnosed synovitis of less than 3 months that disappears by itself) (resolving) and people with established RA 
(diagnosed disease, greater than 3 months’ duration) (A). Anti-FBG staining was observed in areas of fibrosis in inflamed synovia (left panel: red 
anti-FBG, green anti-CD90, blue antipodoplanin) and around areas of vascularisation underneath endothelial cells (centre panel: red anti-FBG, green 
anti-CD31). No staining was observed with isotype controls in place of primary antibodies (right panel). Scale bars 50 µm (B). (C) Mixed populations 
of cells isolated from RA synovial membranes were stimulated with 1 µM recombinant human tenascin-C FBG or 1 ng/mL LPS, which had been 
preincubated with either C3 or isotype control antibody. After 24 hours, supernatants were taken and cytokine ELISAs were performed. Data are 
shown as the mean±SEM from three independent donors. One-way analysis of variance (ANOVA) was performed to determine significance of C3 
inhibition compared with isotype control. *p=0.02, ***p<0.0001. (D–F) Rats were injected with bovine type II collagen intradermally on day 0 and 
day 7. Treatments of PBS (vehicle control) and C3 at 1, 3 or 10 mg/kg were administered twice weekly throughout the experiment by intravenous 
injection (10 animals per treatment group). Animals were scored for clinical signs of disease three times per week, and the mean±SEM is shown (D). 
Paw volumes were measured using a plethysmometer on days 0, 14, 21 and 28, and the mean change±SEM normalised to the day 0 measurements 
is shown (E). Two-way was carried out to test for significance of changes between vehicle and treatment groups. ****p<0.0001, ***p<0.001, 
**p<0.01, *p<0.05. (F) At termination on day 28, hind limbs were assessed for histological signs of inflammation, articular cartilage damage and 
damage to the underlying metaphyseal bone. A χ2 test for trend was used to confirm that the presence or absence of histopathological signs is 
associated with antibody treatment (χ2=9.098, p=0.003), with only 3 of 20 paws were free of any sign of histopathology in the vehicle treated group, 
whereas 11 of 20 paws were disease free in the 10 mg/kg treated group (table). Representative histological images of destructive arthritis (vehicle 
treated) and a normal joint (10 mg/kg) are shown (right panels). FBG, fibrinogen-like globe; IL, interleukin; RA, rheumatoid arthritis; TNF, tumour 
necrosis factor.
 o
n
 20 Decem
ber 2018 by guest. Protected by copyright.
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2018-214294 on 14 Decem
ber 2018. Downloaded from
 
5Aungier SR, et al. Ann Rheum Dis 2018;0:1–6. doi:10.1136/annrheumdis-2018-214294
Basic and translational research
of histopathological changes in the joint (χ2=9.098, p=0.003) 
(figure 3F).
dIsCussIOn
This study describes the production of monoclonal antibodies 
that prevent the FBG domain of tenascin-C from binding to 
and activating TLR4. Staining biopsies of inflamed synovia with 
these antibodies revealed protein expression very early in RA 
and at higher levels than in people with established disease. 
Prophylactic administration of anti-FBG antibodies to rats with 
collagen-induced arthritis did not affect the induction of joint 
inflammation but inhibited disease progression and prevented 
joint damage. These data highlight that early changes in the 
synovial microenvironment contribute to the development of RA 
and that blocking inflammatory signals from the extracellular 
matrix could offer a new therapeutic strategy for treating this 
disease.
Development of anti-FBG antibodies provides evidence of a 
non-redundant role for tenascin-C activation of TLR4 in exper-
imental models of joint inflammation. These antibodies also 
constitute a useful tool with which to learn more about how 
endogenous inflammatory stimuli shape immune responses. 
Both stromal and immune cells express TLR4 in the RA joint; 
identification of biological processes and effector molecules that 
are modulated by FBG blockade in each of these different cell 
types during disease amelioration may reveal new opportunities 
for suppressing inflammation. This will also inform preclinical 
benchmarking studies, for example, if anti-FBG treated animals 
phenocopy tenascin-C null animals, antibody treatment would 
block persistent synthesis of several cytokines from different 
cellular sources, including tumour necrosis factor, interleukin 
(IL)-6 and IL-17,9 raising the possibility that this approach could 
be more effective than single cytokine blockade.
Current approaches to targeting TLR4 in RA focus on anti-
bodies that prevent receptor dimerisation, offering blockade of 
TLR4 activation by a broad range of pathogenic and endoge-
nous ligands.12 13 These antibodies are well tolerated in healthy 
adults and are currently in phase 2a trials in patients with RA,14 
for treatment of TLR4-driven disease defined by serum autoan-
tibody signature.15 Here, we show that targeting a single endog-
enous TLR4 agonist is sufficient to offer therapeutic benefit in 
arthritis models. This strategy could enable a move away from 
blocking TLR4-mediated inflammation at the receptor level, 
hitting only disease-specific stimuli, without engendering global 
immune suppression. Tenascin-C is dispensable for the induction 
of joint inflammation but required for its persistence(figure 3),8 
indicating that its blockade can be used simply to restore the 
resolution of inflammation, without hindering immune defence. 
This premise can now be interrogated by assessing the suscepti-
bility of anti-FBG treated animals to infection, and by compar-
ison of the efficacy and safety profiles of anti-FBG and anti-TLR4 
antibodies. Reducing the risk of opportunistic or recurrent latent 
infection16–19 would be a significant step forward in the manage-
ment of RA.
Treating RA early provides significant clinical benefit to 
patients.20 However, while a myriad of dysregulated signalling 
pathways and cytokine networks contribute to persistent inflam-
mation in well-established disease, events that dictate progres-
sion from early synovitis to chronic joint inflammation and 
tissue destruction remain incompletely understood. This study 
reveals discreet, tenascin-C-rich niches around blood vessels and 
at sites of fibrosis in inflamed synovia, arising early in disease 
development. These data implicate changes in the synovial 
microenvironment in the onset of disease, warranting further 
investigation of the therapeutic window within which anti-FBG 
treatment can achieve efficacy and if this offers a realistic avenue 
for treating people with early disease.
Finally, while antibodies that specifically target FBG highlight 
this domain of tenascin-C as a critical driver of chronic synovial 
inflammation, the capacity of tenascin-C to exert both beneficial 
and deleterious effects across different joint tissues21 illustrates 
a fascinating context specificity for this molecule that remains 
poorly understood. For example, administration of exogeneous 
full-length tenascin-C prevents cartilage degeneration during 
murine models of osteoarthritis22 and promotes cartilage repair 
when applied to osteochondral defects in rabbits.23 It is not yet 
clear whether activation of TLR4 by the FBG domain occurs in 
isolation from, or in synergy with, signalling by other tenascin-C 
domains, how signals from this multidomain molecule are inte-
grated within complex tissue networks and how tissue-specific 
responses to tenascin-C are mediated. While distribution of the 
EGF-L repeats and the FBG domain of tenascin-C overlap in 
inflamed synovia, areas of single antibody positivity may indi-
cate locally elevated availability of the TLR4-activating epitope, 
for example, via tenascin-C conformations that expose the 
FBG domain and conceal the EGF-L repeats, or generation of 
FBG-containing proteolytic fragments. Better understanding 
how different forms of tenascin-C are distributed across different 
tissues, as well as in discreet niches within tissues, will provide 
further mechanistic insight into how this matrix molecule influ-
ences cell behaviour in situ.
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